A PYMNTS Company

US: Appeals court upholds ruling invalidating J&J patent on Remicade

By  |  January 24, 2018

On Tuesday, January 23, a US appeals court upheld a ruling that invalidated a crucial Johnson & Johnson (J&J) patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The US Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a US administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent.

    Remicade generated US sales of US$4.8 billion for J&J in 2016, but it faces increased competition from cheaper “biosimilar” copycats, including Pfizer’s version, which is sold in the United States under the name Inflectra.

    J&J said at the time that it considered Pfizer’s maneuver to be an “at risk” launch, meaning that Pfizer would be liable for money damages to J&J if an appeals court reversed the rulings and upheld the patent.

    Full Content: Bloomberg Quint

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.